A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome - Wikidata - awgldk - TriplyDB

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

http://www.wikidata.org/entity/Q34035391

about

Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Microtubule-binding agents: a dynamic field of cancer therapeutics.Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents.Update: the status of clinical trials with kinase inhibitors in thyroid cancer New para-para stilbenophanes: synthesis by McMurry coupling, conformational analysis and inhibition of tubulin polymerisation.Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.Thyroid cancer: emerging role for targeted therapies.Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division.Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.Cell death signaling and anticancer therapy Anaplastic thyroid carcinoma Approach to the patient with anaplastic thyroid carcinoma.A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer Thyroid cancer: pathogenesis and targeted therapy Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.Anaplastic Thyroid Carcinoma, Version 2.2015.A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.Clinical implications of molecular markers in follicular cell-derived thyroid cancer.Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents.Advances in cellular therapy for the treatment of thyroid cancer.Combretastatin A4 phosphate: a novel vascular disrupting agent.Anaplastic thyroid cancer: a comprehensive review of novel therapy.Targeted therapy in refractory thyroid cancer: current achievements and limitations.The tubulin colchicine domain: a molecular modeling perspective.Pharmacotherapy options for advanced thyroid cancer: a systematic review.Aggressive surgical resection of anaplastic thyroid carcinoma may provide long-term survival in selected patients.Tumour vasculature targeting agents in hybrid/conjugate drugs.Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?Fosbretabulin for the treatment of anaplastic thyroid cancer.Combretastatin A4-phosphate and its potential in veterinary oncology: a review.

P2860

Q26764899-37CBC8BD-08B1-4725-869E-154521AC217F Q27690249-F3B6E950-E12B-4717-BFD9-2C4364B8AC21 Q33560133-5DC21EF1-195F-4961-8B7F-8C7BA3D0135D Q33570056-8CC841B5-95E7-4C6A-A5A0-21AB2CEFC6DD Q33827457-06C6E750-ED57-48AF-B654-444AB619CA3B Q34109712-0C2DB6F0-0530-447B-9A9E-C0A4B0E92666 Q35000792-3ACB4B9C-DE42-4904-89F1-1EC15E70D39E Q35076227-61AD322C-964D-4E58-B1B9-8475AB8F31AD Q35104726-0FA78268-7C3A-4150-B93F-DE7C191043BD Q35370655-8D61D356-243E-4B8F-9148-89067C3525D9 Q35743971-9A1CE381-1B1D-4073-8532-4F363BFAC32D Q35746819-68BFF937-905B-4D6C-B11E-8F096FA77F97 Q35855949-BB36103E-A0B3-42BA-93FA-ACD36D0ECD50 Q35872419-4BA060CE-4F67-4C7C-B727-575B20C6F02A Q35972102-6198261E-AAA6-4950-BC2A-D3ABED460A71 Q36075843-4A0CA56B-A6A5-4BFC-8D39-7B9B24C01DD2 Q36134835-9840EBF7-8CCB-42CF-9608-660FAFAF8029 Q36201492-63172AC5-99A0-4564-B088-0474B1A7AC5D Q36328045-0DDF2B46-2EC1-4329-80A9-C85C1F8508CD Q36813603-49A073A2-7AFE-4398-AA8C-4843684A073E Q36885846-3F8B7CF4-91BB-4415-B9D5-6065D980CE98 Q36929601-E5DE4CF9-328F-4FD3-ABA9-D98611180A5F Q37088201-20EB1A50-2CAF-4736-888D-60DD46D1337F Q37179204-3D21C39B-514C-45D3-9B6D-0CD2CEFCEF0F Q37294597-1C9CD7F6-B053-49CC-BCBD-A368BB3EE3C3 Q37330090-84CEAA6F-E8FA-4D4D-9E93-2CE278947245 Q37526750-F6C17274-A2C6-4142-8153-5D3F4C515C2F Q37611825-DC8C98FC-E43F-410D-94AB-AEE9416B0D45 Q37727669-1DEBE8FE-0716-4A31-8A0C-241883E62D84 Q37776660-3D7EBAFB-6190-45E7-8C3A-E0079EC303AB Q37783616-3E1C891E-7043-4381-8929-DD68B3D1C420 Q37854708-7EB1495F-C98F-499B-97F1-71A2913D7020 Q37875081-99D6C9D0-2CBD-4385-8F2A-1C62E70FD746 Q37944574-10366C48-F34D-410F-9BC5-11111284943A Q37970758-DD7FD952-C730-4FD8-A854-3590B44D731F Q38080420-D9552B30-672D-4C1C-92AA-8566ED94C265 Q38094627-2E3DD8A2-F750-47E0-9D10-2D0DFD9216DB Q38217116-8D5C9BBC-67D4-4A79-AC22-A4D34E3617F6 Q38268163-5FD6C957-27C9-4656-843B-EBA6ACC5BBA4 Q38490875-E51CAC71-290A-41AB-9774-A5A87F0E113D

P2860

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

http://www.wikidata.org/entity/Q34035391

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@ast

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@en

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@nl

type

label

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@ast

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@en

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@nl

prefLabel

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@ast

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@en

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@nl

P1433

Q34035391-9CA0605D-FDDD-4645-9B44-D0C0D9F3E39E

P1476

Q34035391-B358537B-D52E-4135-994B-01EB12708B5A

P2093

Q34035391-11C19E31-239F-4078-9E98-5F420810C21D

Q34035391-22A9676A-33CF-4742-9F69-BAC0BBA2DDDC

Q34035391-2C8F26D8-C63A-4949-8B86-94FCF428F3AA

Q34035391-2DE7BE5F-4FC4-448F-BD30-D7BBE9D97947

Q34035391-578BE0EE-3024-44CE-A55A-C32CC5AA98DE

Q34035391-66026048-1F59-40DD-A437-78A4FE89E996

Q34035391-767240EE-B557-4DAC-A4B2-8853A43CAF3B

Q34035391-98E80658-8C72-4085-9629-7432202808C3

Q34035391-9F81DDBE-2851-4772-B434-D4FFCCA553DD

Q34035391-AB7198AF-2CFD-4989-9A8D-15570757B865

P2860

Q34035391-1C96D2E6-4A20-439B-B318-DC038DC57561

Q34035391-204A2205-E228-45E8-BD0E-C61716D34661

Q34035391-250A486A-20B1-45E2-89F9-9D7DAAF87225

Q34035391-2554D9D8-3CF5-444E-A254-DBA01B792730

Q34035391-38835805-6392-4635-9439-726D6C53E478

Q34035391-3C438517-6B52-4B71-A3AC-5E3B2D10287C

Q34035391-3E17B66B-1558-45F4-BEB5-C16D729B3E6E

Q34035391-576E6F10-DF5C-439A-87B8-D180298DD140

Q34035391-61268418-5DDC-46A9-B286-C4B57890C5E7

Q34035391-63A2C319-55CE-471E-9E18-DEC29BB50932

P304

Q34035391-7DA69BF6-7477-4437-8236-839833861346

P31

Q34035391-204CFEAE-A473-4563-8756-09B392623202

P356

Q34035391-6E6AF57D-A423-4DDA-9F67-FE2311E9941A

P433

Q34035391-ABE1CD2F-7A65-4859-8EC1-46003115C7E3

P478

Q34035391-F21C0F14-A569-4C10-A27C-4F5BAD78790D

P577

Q34035391-624DEB7D-52AD-4D39-B360-BE90B74F3AFE

P5875

Q34035391-B09E9969-1EA7-40A9-9FE8-D7BFFBE1787F

P698

Q34035391-08866F75-A8A0-41E9-96E5-01EEE046E168

P921

Q34035391-AA62627F-8A88-4656-99E5-F19CACF79E36

P932

Q34035391-C7406936-1CA2-48E2-B720-B465A9BEF16B

P356

P1433

P1476

A phase II trial of fosbretabu ...... hesion molecule-1 with outcome

@en

P2093

Afshin Dowlati

http://www.w3.org/2001/XMLSchema#string

Colin J Mooney

http://www.w3.org/2001/XMLSchema#string

Ding Wang

http://www.w3.org/2001/XMLSchema#string

Govardhanan Nagaiah

http://www.w3.org/2001/XMLSchema#string

Jay K Wasman

http://www.w3.org/2001/XMLSchema#string

Jose D Ortiz

http://www.w3.org/2001/XMLSchema#string

Joseph A Bokar

http://www.w3.org/2001/XMLSchema#string

Matthew M Cooney

http://www.w3.org/2001/XMLSchema#string

Panos S Savvides

http://www.w3.org/2001/XMLSchema#string

Paul H Hartman

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

Cancer statistics, 2007

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Phase I trial of combretastatin a-4 phosphate with carboplatin.

Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.

P304

233-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2008.0321

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24181303

http://www.w3.org/2001/XMLSchema#string

P698

19265494

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2913806

http://www.w3.org/2001/XMLSchema#string